Soleno Therapeutics Faces Scrutiny as Stock Plummets After Scorpion Report Soleno Therapeutics shares dive following a critical report by Scorpion Capital, raising concerns about its core drug, VYKAT™ XR.

Soleno Therapeutics Faces Scrutiny as Stock Plummets After Scorpion Report #USA #San_Francisco #VYKAT_XR #Soleno_Therapeutics #Scorpion_Capital